MG
RNTX

Michael Gelband’s Rein Therapeutics RNTX Stock Holding History

Michael Gelband’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,505
Closed -$31K – 2684
2021
Q3 		$31K Buy
1,505
+350
+30% +$7.67K ﹤0.01% 2001
2021
Q2 		$29K Buy
+1,155
New +$28.8K ﹤0.01% 2248

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Michael Gelband's RNTX Position: Q4 2021 in Review

Michael Gelband sold out of Rein Therapeutics (RNTX) in Q4 2021, closing a stake of 1,505 shares — an estimated $31K sold.

Michael Gelband first reported a position in RNTX in Q2 2021 and held it in 2 quarters. The position peaked at $31K in Q3 2021. 43 funds tracked by Wall St. Rank hold RNTX as of Q4 2021.

  • Michael Gelband reported no remaining Rein Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Michael Gelband sold 1,505 Rein Therapeutics shares in Q4 2021, an estimated $31K.
  • Michael Gelband first reported a position in Rein Therapeutics in Q2 2021 and held it in 2 quarters.
  • Michael Gelband's Rein Therapeutics position peaked at $31K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.